CSL shares rose as much as 2% to A$154.21, helping spur a 0.4% rise in the ASX 200. CSL shares also recovered some ground after logging steep losses last week. Get more breaking news on major ...
CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...
Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, ...
CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...
Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise ...
CSL Ltd (ASX: CSL) shares are slipping today. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $152.17. In late morning trade on Tuesday, shares are changing hands ...
Thursday, February 12, 2026: The Club says it’ll trim its position in this power giant following a strong rally Got a confidential news tip? We want to hear from you. Sign up for free newsletters and ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
About DuPont de Nemours Inc. DuPont de Nemours, Inc. is a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results